Inhalational therapies for the ICU

Area of Science:

• Critical Care Medicine
• Pulmonology
• Pharmacology

Background:

• Intravenous drug administration is standard in ICUs.
• Novel inhaled agents and alternative routes for existing drugs are emerging.
• These approaches aim to reduce systemic toxicity and enhance therapeutic effectiveness.

Purpose of the Study:

• To review the current applications and evidence for inhaled therapies in the intensive care unit (ICU).
• To evaluate the efficacy of aerosolized antibiotics, inhaled nitric oxide, heliox, and other inhaled agents.
• To discuss the role of inhaled therapies in managing pneumonia, secretion clearance, and cardiac emergencies.

Main Methods:

• Review of current literature on inhaled drug delivery in critical care.
• Analysis of evidence for specific inhaled agents including antibiotics, nitric oxide, and heliox.
• Assessment of therapies for secretion management and their supporting data.

Main Results:

• Aerosolized antibiotics show promise in treating pneumonia, including drug-resistant strains, and reducing ventilator-associated pneumonia.
• Inhaled nitric oxide is established in neonatal care with limited adult ICU data.
• Helium-oxygen (Heliox) mixtures offer symptomatic relief for airway obstruction, but routine use is limited by technical challenges.

Conclusions:

• Inhaled antimicrobials offer benefits for select pneumonia patients.
• Inhaled nitric oxide has a defined role in neonatal intensive care and a limited role in adult intensive care.
• Heliox provides symptom relief, but technological challenges limit routine use; secretion management relies on humidification and suctioning.